International standard reagents for HPV detection

Disease Markers

Volumn 23, Issue 4, 2007, Pages 283-296

  Pagliusi, Sonia R ^a   Garland, Suzanne M ^b,c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b ROYAL WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cervical cancer; Diagnostic; Genital infection; Hybridization; Papillomavirus; PCR; Serology; Vaccine

Indexed keywords

REAGENT; VIRUS DNA; VIRUS PROTEIN;

ANTIBODY DETECTION; CYTOLOGY; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; STANDARD; VIRUS DETECTION; VIRUS NEUTRALIZATION; WART VIRUS;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 34347336647     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/591826     Document Type: Review

References (74)

1. J.G. Baseman and L.A. Koutsky, The epidemiology of human papillomavirus infections, J Clin Virol 1 (2005), 16-24.
2. J.J. Carter, M.M. Madeleine, K. Shera, S.M. Schwartz, K.L., Cushing-Haugen, G.C. Wipf, P. Porter, J.R. Daling, J.K. McDougall and D.A. Galloway, Human papillomavirus, 16and 18 L1 serology compared across anogenital cancer sites, Cancer Res 61 (2001), 1934-1940.
3. X. Castellsague and N. Munoz, Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking, J Natl Cancer Inst Monogr 31 (2003), 20-28.
4. P.E. Castle, D. Solomon, M. Schiffman and C.M. Wheeler for the ALTS Group, Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities, J Nat Can Inst 97 (2005), 1066-1071.
5. G.M. Clifford, S. Gallus, R. Herrero, N. Munoz, P.J. Snijders, S. Vaccarella, P.T. Anh, C. Ferreccio, N.T. Hieu, E. Matos, M. Molano, R. Rajkumar, G. Ronco, S. de Sanjose, H.R. Shin, S. Sukvirach, J.O. Thomas, S. Tunsakul, C.J. Meijer and S. Franceschi, IARC HPV Prevalence Surveys Study Group, Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis, Lancet 366 (2005), 991-998.
6. G.M. Clifford, J.S. Smith, M. Plummer, N. Munoz and S. Franceschi, Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis, Br J Cancer 88 (2003), 63-73.
7. R. Closas Garcia, X. Castellsague, X. Bosch and C.A. Gonzalez, The role of diet and nutrition in cervical carcinogenesis: a review of recent evidence, Int J Cancer 117 (2005), 629-637.
8. J. Cuzick, A. Szarewski, H. Cubie, G. Hulman, H. Kitchener, D. Luesley, E. McGoogan, U. Menon, G. Terry, R. Edwards, C. Brooks, M. Desai, C. Gie, L. Ho, I. Jacobs, C. Pickles and P. Sasieni, Management of women who test positive for highrisk types of human papillomavirus: the HART study, Lancet 362 (2003), 1871-1876.
9. D. Dias, J. Van Doren, S. Schlottmann, S. Kelly, D. Puchalski, W. Ruiz, P. Boerckel, J. Kessler, J.M. Antonello, T. Green, M. Brown, J. Smith, N. Chirmule, E. Barr, K.U. Jansen and M.T. Esser, Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18, Clin Diagn Lab Immunol 8 (2005), 959-969.
10. K. Elfgren, M. Jacobs, J.M. Walboomers, C.J. Meijer and J. Dillner, Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia, Obstet Gynecol 100 (2002), 965-971.
11. M. Ferguson, A. Heath, S. Johnes, S. Pagliusi and J. Dillner, Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses, Int J Cancer 118 (2005), 1508-1514.
12. D. Galloway, Papillomavirus vaccines in clinical trials, Lancet Infect Dis 8 (2003), 469-475.
13. L. Gustafsson, J. Pontén, M. Zack and H.-O. Adami, International incidence rates of invasive cervical cancer after introduction of cytological screening, Cancer Causes Cont 8 (1997), 755-763.
14. D.M. Harper, E.L. Franco, C. Wheeler, D.G. Ferris, D. Jenkins, A. Schuind, T. Zahaf, B. Innis, P. Naud, N.S. deCarvalho, C.M. Roteli-Martins, J. Teixeira, M.M. Blattetr, A.P. Korn, W. Quint and G. Dubin, GlaxoSmithKline HPV Vaccine Study Group, Efficacy of a bivalent L1 virus like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial, Lancet 364 (2004), 1757-1765.
15. C.D. Harro, Y.Y. Pang, R.B. Roden, A. Hildesheim, Z. Wang, M.J. ReyNOlds, T.C. Mast, R. Robinson, B.R. Murphy, R.A. Karron, J. Dillner, J.T. Schiller and D. Lowy, Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine, J Natl Cancr Inst 93 (2001), 284-292.
16. H. zur Hausen, Condylomata acuminata and human genital cancer, Cancer Res 36 (1976), 794.
17. H. zur Hausen, Papillomavirus and cancer: from basic studies to clinical application, Nat Rev Cancer 5 (2002), 342-350.
18. G.Y. Ho, R. Bierman, L. Beardsley, C.J. Chang and R.D. Burk, Natural history of cervicovaginal papillomavirus infection in young women, N Engl J Med 338 (1998), 423-428.
19. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 2005, http://monographs.iarc.fr/ENG/Meetings/90-hpv.pdf.
20. T. Iftner and L.L. Villa, Chapter 12: Human papillomavirus technologies, J Natl Cancer Inst Monogr 31 (2003), 80-88.
21. C. Jennings, S.A. Fiscus, S.M. Crowe, A.D. Danilovic, R.J. Morack, S. Scianna, A. Cachafeiro, D.J. Brambilla, J. Schupbach, W. Stevens, R. Respess, O.E. Varnier, G.E. Corrigan, J.S. Gronowitz, M.A. Ussery and J.W. Bremer, Comparison of Two Human Immunodeficiency Virus (HIV) RNA Surrogate Assays to the Standard HIV RNA Assay, J Clin Microbiol 43 (2005), 5950-5956.
22. A. Josefsson, K. Livak and U. Gyllensten, Detection and quantitation of human papillomavirus by using the fluorescent 5′exonuclease assay, J Clin Microbiol 37 (1999), 490-496.
23. J.T. Keating, A. Cviko, S. Riethdorf, L. Riethdorf, B.J. Quade, D. Sun, S. Duensing, E.E. Sheets, K. Munger and C.P. Crum, Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia, Am J Surg Pathol 25 (2001), 884-891.
24. R. Kirnbauer, Papillomavirus-like particles for serology and vaccine development, Intervirology 39 (1996), 54-61.
25. T. Kiyono, A. Hiraiwa, M. Fujita, Y. Hayashi, T. Akiyama and M. Ishibashi, Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein, Proc Natl Acad Sci 94 (1997), 11612-11616.
26. R. Klaes, T. Friedrich, D. Spitkovsky, R. Ridder, W. Rudy, U. Petry, G. Dallenbach-Hellweg, D. Schmidt and M. von Knebel Doeberitz, Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri, Cancer Res 59 (1999), 6132-6136.
27. J.R. Kornegay, M, Roger, P.O. Davies, A.P. Shepard, N.A. Guerrero, B. Lloveras, D. Evans and F. Coutlee, International proficiency study of a consensus L1 PCR assay for the detection and typing of human papillomavirus DNA: evaluation of accuracy and intralaboratory and interlaboratory agreement, J Clin Microbiol 41 (2003), 1080-1086.
28. L.A. Koutsky, K.A. Ault, C.M. Wheeler, D.R. Brown, E. Barr, F.B. Alvarez, L.M. Chiacchierini and K.U. Jansen, Proof of Principle Study Investigators, A controlled trial of a human papillomavirus type 16 vaccine, N Engl J Med 347 (2002), 1645-1651.
29. M. Lehtinen, M. Pawlita, K. Zumbach, K. Lie, M. Hakama, E. Jellum, P. Koskela, T. Luostarinen, J. Paavonen, E. Pukkala, E. Sigstad, S. Thoresen and J. Dillner, Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later, Am J Obstet Gynecol 188 (2003), 49-55.
30. A.K. Lie, B. Risberg, B. Borge, B. Sandstad, J. Delabie, R. Rimala, M. Onsrud and S.Thoresen, DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia, Gynecol Onco 97 (2005), 908-915.
31. A. Lorincz and J. Anthony, Advances in HPV detection by Hybrid Capture, Papillomavirus Report 12 (2001), 145-154.
32. th edition, eds, Williams & Wilkins, 2001.
33. C. Mao, L.A. Koutsky, K.A. Ault, C.M. Wheeler, D.R. Brown, D.J. Wiley, F.B. Alvarez, O.M. Bautista, K.U. Jansen and E. Barr, Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial, Obstet Gynecol 107 (2006), 18-27.
34. D.J. Marais, J.M. Best, R.C. Rose, P. Keating, R. Soeters, L. Denny, C.M. Dehaeck, J, Nevin, P. Kay, J.A. Passmore and A.L. Williamson, Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia, J Med Virol 65 (2001), 149-154.
35. K. Middleton, W. Peh, S. Southern, H. Griffin, K. Sotlar, T. Nakahara, A. El-Sherif, L. Morris, R. Seth, M. Hibma, D. Jenkins, P. Lambert, N. Coleman and J. Doorbar, Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers, J Virol 77 (2003), 10186-10201.
36. J. Monsonego, J.M. Bohbot, G. Pollini, C. Krawec, C. Vincent, I. Merignargues, F. Haroun, P. Sednaoui, L. Monfort, R. Dachez and K. Syrjanen, Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear, Gynecol Onco 99 (2005), 160-168.
37. N. Munoz, F.X. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, K.V. Shah, P.J. Snijders and C.J. Meijer, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group, Epidemiologic classification of human papillomavirus types associated with cervical cancer, N Engl J Med 348 (2003), 518-527.
38. D. Nardelli-Haefliger, D. Wirthner, J.T. Schiller, D.R. Lowy, A. Hildesheim, F. Ponci and P. De Grandi, Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles, J Natl Cancer Inst 95 (2003), 1128-1137.
39. M.A. Nobbenhuis, T.J. Helmerhorst, A.J. van den Brule, L. Rozendaal, P.D. Bezemer, F.J. Voorhorst and C.J. Meijer, High-risk human papillomavirus clearance in pregnant women: trends for lower clearance during pregnancy with a catchup postpartum, Br J Cancer 87 (2002), 75-80.
40. P. Ohlschlager, W. Osen, K. Dell, S. Faath, R.L. Garcea, I. Jochmus, M. Muller, M. Pawlita, K. Schafer, P. Sehr, C. Staib, G. Sutter and L. Gissmann, Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice, J Virol 77 (2003), 4635-4645.
41. D. Opalka, C.E. Lachman, S.A. MacMullen, K.U. Jansen, J.F. Smith, N. Chirmule and M.T. Esser, Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay, Clin Diagn Lab Immunol 10 (2003), 108-115.
42. A.G. Östör, Natural history of cervical intraepithelial neoplasia: A critical review, Int J Gynecol Pathol 12 (1993), 86-92.
43. G.N. Papanicolaou and H.F. Traut, The diagnostic value of vaginal smears in carcinoma of uterus, Am J Obstet Gynecol 42 (1941), 193-205.
44. D.M. Parkin, The global health burden of infection-associated cancers in the year 2002, Int J Cancer 118 (2006), 3030-3044.
45. D.M. Parkin, F. Bray, J. Ferlay and P. Pisani, Global cancer statistics 2002, CA Cancer J Clin 55 (2005), 74-108.
46. D.V. Pastrana, C.B. Buck, Y.Y. Pang, C.D. Thompson, P.E. Castle, P.C. FitzGerald, S. Kruger Kjaer, D.R. Lowy and J.T. Schiller, Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18, Virology 321 (2004), 205-216.
47. W. Quint, S.R. Pagliusi, N. Lelie, E.-M. de Villiers, C.M. Wheeler and the World Health Organization Human Papillomavirus DNA International Collaborative Study Group, Results of the First World Health Organization International Collaborative Study of Detection of Human Papillomavirus DNA, J Clin Microbiol 44 (2006), 571-579.
48. R.B. Roden, N.L. Hubbert, R. Kirnbauer, N.D. Christensen, D.R. Lowy and J.T. Schiller, Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition, J Virol 70 (1996), 3298-3301.
49. J. Saldanha, A. Heath, N. Lelie, G. Pisani and M.Y. Yu, Collaborative Study Group, A World Health Organization International Standard for hepatitis A virus RNA nucleic acid amplification technology assays, Vox Sang 89 (2005), 52-58.
50. J.T. Schiller, Papillomavirus-like particle vaccines for cervical cancer, Mol Med Today 5 (1999), 209-215.
51. J. Schirm, A.M. van Loon, E. Valentine-Thon, P.E. Klapper, J. Reid and G.M. Cleator, External quality assessment program for qualitative and quantitative detection of hepatitis C virus RNAin diagnostic virology, J Clin Microbiol 40 (2002), 2973-2980.
52. N.F. Schlecht, Prognostic value of human papillomavirus in the survival of head and neck cancer patients: an overview of the evidence, Oncol Rep 14 (2005), 1239-1247.
53. M. Schmitt, I.G. Bravo, P.J. Snijders, L. Gissmann, M. Pawlita and T.Waterboer, Bead-based multiplex genotyping of human papillomaviruses, J Clin Microbiol 44 (2006), 504-512.
54. P. Sehr, M. Muller, R. Hoepfl, A. Widschwendter and M. Pawlita, HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase, J Virol Meth 106 (2002), 61-70.
55. S.S. Seo, Y.S. Song, J.W. Kim, N.H. Park, S.B. Kang and H.P. Lee, Good correlation of HPV DNA test between self-collected vaginal and clinician-collected cervical samples by the oligonucleotide microarray, Gynecol Oncol 102 (2006), 67-73.
56. H.R. Shin, S. Franceschi, S. Vaccarella, J.W. Roh, Y.H. Ju, J.K. Oh, H.J. Kong, S.H. Rha, S.I. Jung, J.I. Kim, K.Y. Jung, L.J. van Doorn and W. Quint, Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea, J Infect Dis 190 (2004), 468-476.
57. I. Silins, E. Avall-Lundqvist, A. Tadesse, K.U. Jansen, U. Stendahl, P. Lenner, K. Zumbach, M. Pawlita, J. Dillner and B. Frankendal, Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients, Gynecol Oncol 85 (2002), 333-338.
58. J.S. Smith, C. Bosetti, N. Munoz, R. Herrero, F.X. Bosch, J. Eluf-Neto, C.J. Meijer, A.J. Van Den Brule, S. Franceschi and R.W. Peeling, IARC multicentric case-control study, Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study, Int J Cancer 111 (2004), 431-439.
59. P.J. Snijders, A.J. van den Brule and C.J. Meijer, The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity, J Pathol 201 (2003), 1-6.
60. Technical workshop on international collaborative studies on HPV reagents for laboratory diagnostic procedures: a progress report. http://www.who.int/ vaccines-documents/DocsPDF04/www786.pdf.
61. L.L. Villa, R.L. Costa, C.A. Petta, R.P. Andrade, K.A. Ault, A.R. Giuliano, C.M. Wheeler, L.A. Koutsky, C. Malm, M. Lehtinen, F.E. Skjeldestad, S.E. Olsson, M. Steinwall, D.R. Brown, R.J. Kurman, B.M. Ronnett, M.H. Stoler, A. Ferenczy, D.M. Harper, G.M. Tamms, J. Yu, L. Lupinacci, R. Railkar, F.J. Taddeo, K.U. Jansen, M.T. Esser, H.L. Sings, A.J. Saah and E. Barr, Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial, Lancet Oncol 6 (2005), 271-278.
62. S. Vinokurova, N. Wentzensen and M. von Knebel Doeberitz, Analysis of p16INK4a and integrated HPV genomes as progression markers, Methods Mol Med 119 (2005), 73-83.
63. J.M. Walboomers, M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A. Kummer, K.V. Shah, P.J. Snijders, J. Peto, C.J. Meijer and N. Munoz, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J Pathol 189 (1999), 12-19.
64. X. Wang, M. Sapp, N.D. Christensen and J. Dillner, Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology, J Gen Virol 85 (2005), 65-73.
65. T. Waterboer, P. Sehr, K.M. Michael, S. Franceschi, J.D. Nieland, T.O. Joos, M.F. Templin and M. Pawlita, Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins, Clin Chem 51 (2005), 1845-1853.
66. T. Waterboer, P. Sehr and M. Pawlita, Suppression of non-specific binding in serological Luminex assays, J Immunol Methods 309 (2005), 200-204.
67. N. Wentzensen, C. Bergeron, F. Cas, D. Eschenbach, S. Vinokurova and M. von Knebel Doeberitz, Evaluation of a nuclear score for p16INK4a-stained cervical squamous cells in liquid-based cytology samples, Cancer 105 (2005), 461-467.
68. WHO Expert Committee on Biological Standardization, Fifty-third Report, http://www.who.int/biologicals/926-Inside%20page.pdf.
69. WHO informal workshop: development of international HPV reference reagents, 2001. http://www.who.int/vaccinesdocuments/DocsPDF02/www699.pdf.
70. WHO Technical workshop on cellular mediated immunity to human papillomavirus, 2005. http://www.who.int/vacciesdocuments/DocsPDF06/824scxreen. pdf.
71. WHO Technical Report Series http://whqlibdoc.who.int/trs/WHO_TRS_897.pdf.
72. T.C. Wright, L. Denny, L. Kuhn, A. Pollack and A. Lorincz, HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, JAMA 283 (2000), 81-86.
73. T.C. Wright, M. Schiffman, D. Solomon, J. Cox, F. Garcia, S. Goldie, K. Hatch, K. Noller, N. Roach, C. Runowicz and D. Saslow, Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening, Obstet Gynecol 103 (2004), 304-309.
74. N. Ylitalo, P. Sorensen, A.M. Josefsson, P.K. Magnusson, P.K. Andersen, J. Ponten, H.O. Adami, U.B. Gyllensten and M. Melbye, Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study, Lancet 355 (2000), 2194-2198.